SCHEMBL4034698

SCHEMBL4034698

COc1cc(-c2oc3cc(O)cc(O)c3c(=O)c2O)cc(OC)c1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 5/20 1.00
CYP1A1 P04798 6/20 0.76
CYP1A2 P05177 6/20 0.76
CYP1B1 Q16678 6/20 0.76
XDH P47989 5/20 0.76
MEN1 O00255 5/20 0.76
KMT2A Q03164 5/20 0.76
IPMK Q8NFU5 3/20 0.76
IP6K2 Q9UHH9 3/20 0.76
CA12 O43570 3/20 0.76
PPARG P37231 3/20 0.76
CA7 P43166 3/20 0.76
CA2 P00918 2/20 0.76
CA4 P22748 2/20 0.76
FTO Q9C0B1 4/20 0.67
MAOA P21397 3/20 0.67
CYP3A4 P08684 5/20 0.67
CYP2D6 P10635 5/20 0.67
KDM4E B2RXH2 4/20 0.67
MAPT P10636 4/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30255771 1.00 ABCB1 (1.00) ABCB1CYP1A1CYP1A2CYP1B1XDH
Syringetin SCHEMBL29929167 0.92 ABCB1 (0.85) ABCB1CYP1A1CYP1A2CYP1B1XDH
Syringetin SCHEMBL810981 0.92 ABCB1 (0.85) ABCB1CYP1A1CYP1A2CYP1B1XDH
Laricytrin SCHEMBL19213534 0.91 ABCB1 (0.83) ABCB1CYP1A1CYP1A2CYP1B1XDH
Laricytrin SCHEMBL29929477 0.91 ABCB1 (0.83) ABCB1CYP1A1CYP1A2CYP1B1XDH
Mearnsetin SCHEMBL3690508 0.90 ABCB1 (0.81) ABCB1CYP1A1CYP1A2CYP1B1XDH
SCHEMBL19249162 0.88 ABCB1 (0.78) ABCB1CYP1A1CYP1A2CYP1B1XDH
SCHEMBL3452793 0.87 ABCB1 (0.77) ABCB1CYP1A1CYP1A2CYP1B1XDH
SCHEMBL3211188 0.86 MEN1 (0.86) ABCB1CYP1A1CYP1A2CYP1B1XDH
Isorhamnetin SCHEMBL19235 0.86 MEN1 (1.00) ABCB1CYP1A1CYP1A2CYP1B1XDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115927238-B Glycyrrhiza oxymethyl transferase and application thereof 中国科学院华南植物园 2023-08-01 CN claimed
CN-115927238-A Glycyrrhiza uralensis oxygen methyltransferase and application thereof 中国科学院华南植物园 2023-04-07 CN claimed
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US claimed
US-20040242503-A1 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease ATTENTION LABS INCORPORATED 2004-12-02 US claimed
EP-1267853-B1 COMPOSITIONS COMPRISING BLOCKERS OF L-DOPA RENAL CELL TRANSFER FOR THE TREATMENT OF PARKINSON'S DISEASE PORTELA & CA SA (PT) 2004-09-08 EP claimed
JP-2003504327-A 2003-02-04 JP claimed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP claimed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO claimed
CN-115927238-B Glycyrrhiza oxymethyl transferase and application thereof 中国科学院华南植物园 2023-08-01 CN disclosed
CN-115927238-A Glycyrrhiza uralensis oxygen methyltransferase and application thereof 中国科学院华南植物园 2023-04-07 CN disclosed
EP-3763419-A1 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES Anji Pharma (US) LLC (US) 2021-01-13 EP disclosed
EP-2661266-B1 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES ANJI PHARMA (US) LLC (US) 2020-09-16 EP disclosed
US-9962344-B2 Chemosensory receptor ligand-based therapies ELCELYX THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-9962344-B2 Chemosensory receptor ligand-based therapies ELCELYX THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
WO-2003057210-A1 COMPOSITIONS AND METHODS FOR INCREASING CELL PROLIFERATION COMPRISING A FLAVONOID KIMBERLY-CLARK WORLDWIDE, INC. (US) 2003-07-17 WO disclosed
US-20030125264-A1 Methods For Treating Wounds KIMBERLY-CLARK WORLDWIDE, INC. 2003-07-03 US disclosed
US-6555523-B1 Such as 3',4'-diacetoxy-5,6,7-trimethoxyflavone or naringin in the treatment HIV, picornavirus, and/or respiratory virus CASCADE ESTATES LTD. (MU) 2003-04-29 US disclosed
US-6506792-B1 Breast and endometrial cancers are major causes of death in Western women. In particular, tumours in endocrine-dependent tissues, such as the breast and endometrium, occur most frequently in postmenopausal women at a time when the ovaries STERIX LIMITED (GB) 2003-01-14 US disclosed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP disclosed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242503-A1 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease COMT, DDC, AADAT ABCB1 54/4885CYP1A1 1911/4885CYP1A2 3132/4885
US-20030125264-A1 Methods For Treating Wounds FGF2, MMP1, FIBP ABCB1 2498/4885CYP1A1 1856/4885CYP1A2 1713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.